Clinical Trial Update: Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma [Phase 1]

View source ↗

Summary

An update on a Phase 1 trial of oblimersen in combination with gemcitabine for patients with advanced solid tumors or lymphoma, which has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Hodgkin Lymphoma
• Lymphoblastic Lymphoma
• Mantle Cell Lymphoma
• Nodal Marginal Zone B-cell Lymphoma

Drugs mentioned

• Gemzar (gemcitabine)
• Genasense (oblimersen)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 | Status: TERMINATED